C
Cornelia Weber
Researcher at Hoffmann-La Roche
Publications - 17
Citations - 1156
Cornelia Weber is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Pharmacokinetics & Bosentan. The author has an hindex of 13, co-authored 17 publications receiving 1112 citations. Previous affiliations of Cornelia Weber include University of Zurich & University of Bern.
Papers
More filters
Journal ArticleDOI
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Karin Fattinger,Karin Fattinger,Karin Fattinger,Christoph Funk,Christoph Funk,Christoph Funk,Michael Pantze,Michael Pantze,Michael Pantze,Cornelia Weber,Cornelia Weber,Cornelia Weber,Jürg Reichen,Jürg Reichen,Jürg Reichen,Bruno Stieger,Bruno Stieger,Bruno Stieger,Peter J. Meier,Peter J. Meier,Peter J. Meier +20 more
TL;DR: In this study, inhibition of the hepatocanalicular bile salt export pump (rodents, Bsep; humans, BSEP ABCB11) could account for bosentan‐induced liver injury.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Cornelia Weber,Rita Schmitt,Herbert Birnboeck,Gérard Hopfgartner,Sjoerd P. van Marle,Pierre Peeters,Jan H. G. Jonkman,Charles-Richard Jones +7 more
TL;DR: Bosentan (Ro 47‐0203) is a potent and mixed ETA‐ and ETB‐receptor antagonist that has been studied in a variety of preclinical disease models.
Journal Article
Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects.
TL;DR: Hepatic metabolism followed by biliary excretion of the metabolites apparently represents the major pathway of elimination for bosentan in humans.
Journal ArticleDOI
Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Bosentan, an Endothelin Receptor Antagonist, in Healthy Male Volunteers
Cornelia Weber,Rita Schmitt,Herbert Birnboeck,Gérard Hopfgartner,Herwig Eggers,Joseph Meyer,Sjoerd P. van Marle,Henk W. Viischer,Jan H. G. Jonkman +8 more
TL;DR: The multiple‐dose pharmacokinetics, safety, and tolerability of oral bosentan, a selective endothelin receptor antagonist, were investigated in healthy male volunteers and the drug was very well tolerated.
Journal ArticleDOI
Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.
TL;DR: Bosentan treatment led to a statistically significant reduction of the maximal prothrombin time (PTmax) and the AUC0‐120h of PT and factor VII activity compared to placebo, on average, by 23% to 38%, which could be explained by an increase in the elimination of the pharmacologically more active S‐enantiomer.